Randomized trial · people
Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1
Checked against the paper Randomized trialPublished by PepVault
The takeaway
For people with obesity and prediabetes, this trial shows weight loss held up over about 3 years on tirzepatide and far fewer people developed type 2 diabetes than on placebo.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 1032
- Published
- 2025
- Journal
- N Engl J Med
What they tested
The team tested whether 3 years of weekly tirzepatide lowers weight and delays type 2 diabetes in people with obesity and prediabetes, and looked at its safety.
How the study was done
A phase 3, double-blind, randomized, placebo-controlled trial that enrolled 2539 people with obesity. This analysis covers the 1032 who also had prediabetes and got once-weekly tirzepatide at 5 mg, 10 mg or 15 mg, or placebo (an inactive comparison), for 176 weeks, then 17 weeks off treatment.

Model. Individual results vary.
What they found
At 176 weeks, average body weight changed by -12.3% in the 5 mg arm, -18.7% in the 10 mg arm and -19.7% in the 15 mg arm, versus -1.3% on placebo. Type 2 diabetes was diagnosed in 1.3% of the tirzepatide groups versus 13.3% of the placebo group (hazard ratio 0.07, 95% CI 0.0 to 0.1). After 17 weeks off treatment, the figures were 2.4% versus 13.7% (hazard ratio 0.12, 95% CI 0.1 to 0.2). Apart from COVID-19, the most common side effects were gastrointestinal, mostly mild to moderate and mainly in the first 20 weeks while doses were being raised, and the trial found no new safety signals.
What it doesn’t show
This covers only the participants who had prediabetes, and it followed them for 17 weeks after stopping, so it does not show what happens over a longer time off the drug. The trial was funded by Eli Lilly.
The paper
Jastreboff et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025.
The compound
More studies on Tirzepatide
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZERandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeksRandomized trial · people · 2025
- Tirzepatide: up to 17.5% weight loss at 52 weeks in SURMOUNT-CNRandomized trial · people · 2024
- Every study on Tirzepatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.